NYSE: COO- In a letter that was delivered to investors on Monday, August 29, the equity research analysts at KeyCorp decreased their projections for the earnings per share (EPS) that the shares of the Cooper Companies would generate in the third quarter of 2022.
The letter was given to investors on the same day. A KeyCorp analyst named M. Mishan predicted that the medical device business would earn $3.11 per share in the fourth quarter. This figure is significantly lower than the $3.26 per share initially projected to be earned by the industry. Research firms have given the stock of KeyCorp the rating of “Overweight,” and the price objective they have set is $408.0. According to the most recent and most accurate assessment, it is projected that The Cooper Companies will bring in a profit of $13.15 per share throughout the entire year. In addition, KeyCorp predicted that Cooper Companies would bring in $3.44 in revenue during the last quarter of the fiscal year 2022 and $13.03 overall for the entire year. On June 2, 2018, Cooper Companies (NYSE: COO) made public its most recent quarterly results report on a Thursday.
This report covered the period ending March 31, 2018. The medical equipment manufacturer declared a quarterly profit of $3.24 per share, which was $0.17 less than the consensus forecast of $3.41 per share among market experts. In the case of Cooper Companies, the return on equity was 9.48%, while the net margin for the company was 30.20%. The actual revenue for the quarter came in at $829.80 million, which was far more than the sum of $821.03 million that industry analysts had anticipated it would be. The company’s earnings per share came in at $3.38, which is a significant increase compared to the prior year’s performance for the same period. Compared to the previous fiscal year, the company’s sales saw a 15.3% increase. Many supplementary reports have brought the Chief Operating Officer to the forefront. On Friday, July 8, Piper Sandler released a research report that rated Cooper Companies as “overweight” and lowered the price objective for the company from $425 to $375.
The study was published. “Cooper Companies Research Update” was the title of the study that was presented. In a research report made public on Wednesday, August 24, Baird lowered their price target on Cooper Companies from $392.00 to $375.00 and gave the company a “neutral” rating in a research report. It is where the analysis was published. Wells Fargo & Company lowered the price objective for Cooper Companies was lowered by Wells Fargo & Company in a research report published on Wednesday, August 10.
The new price target is $370.00, down from $380.00 previously. Despite this move, the company was nevertheless given an “overweight” rating by the investment firm. Stifel Nicolaus lowered their price objective on Cooper Companies from $475.00 to $450.00 in a research report made available to the general public on Monday, June 6 in a research report made available to the general public on Tuesday, June 7. And finally, in a research note published on Friday, June 3, Stephens decreased their “overweight” rating on Cooper Companies and their price objective, which had previously been set at $500 but was now reduced to $460.
Both of these changes were made in response to recent market events. Eight equity research specialists have provided the stock with a buy rating, while the remaining three have urged investors to maintain their current holdings. The company has been given an average recommendation of “Moderate Buy,” and its price target has been set at $423.78, as indicated by the data provided by Bloomberg. Cooper Companies’ stock began trading for the first time on Tuesday for $291.30.
The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.69, and a current ratio of 1.05 in its operations. The moving average value for the company over the past 50 days is presently resting at $315.65, and the moving average value over the past 200 days is currently sitting at $355.10. During the last year, the price of Cooper Companies stock has ranged from a low of $284.01 to a high of $463.59. The current price of the stock is $284.01. The company’s market value is $14.37 billion, and the price-to-earnings ratio for the company is 15.30.
This item has a PEG ratio of 2.26, and its beta value is 0.90. The value of this item is $0.90. In addition, the business disclosed that it would be disbursing a dividend on August 11, which is the date that corresponds to the mid-year point in time. On Wednesday, July 27, dividends for $0.03 per share were distributed to shareholders on record as of that day. The first day of the distribution period, which was July 26 and marked the beginning of the dividend payout period, was Tuesday.
At this time, Cooper Companies has a dividend payout ratio of 0.32%, also referred to as the DPR. Over the past few months, several hedge funds and other forms of institutional investors have bought and sold COO shares. American Century Companies Inc. boosted the percentage of ownership it owned in Cooper Companies by 25.1% during the final three months of 2018. Following the acquisition of a further 457 shares during the period, American Century Companies Inc. now holds 2,275 shares of the medical device company’s stock, valued at $953 million. Natixis Advisors L.P. achieved a 16.6% growth in the value of its investment in Cooper Companies during the final three months of 2018.
Natixis Advisors L.P. now has 21,889 shares of the medical device firm with a market cap of $9,170,000 in its possession. This comes from purchasing an additional 3,116 shares during the most recent quarter. First Republic Investment Management Inc. boosted the percentage of Cooper Companies shares it owned by 20.7% during the fourth quarter. First Republic Investment Management Inc. now has 2,080 shares of the medical device company’s stock, valued at $870,000, thanks to purchasing an additional 357 shares during the most recent quarter. Over the final three months of 2018, Korea Investment Corp achieved a 12.7% growth in its holdings of the Cooper Companies.
After making an additional purchase of 1,000 shares during the most recent quarter, Korea Investment Corp now has 8,900 shares, giving it a market capitalization of $3,729,000. It is because Korea Investment Corp now has a total of 8,900 of the company’s shares. And finally, during the final three months of 2018, We Are One Seven LLC increased its holdings in Cooper Companies by 49.5% by purchasing additional shares. We Are One Seven LLC now has 1,904 shares of the medical device company with a market cap of $798 million.
This is because, during the most recent quarter, the company made an additional purchase of 630 shares, bringing the total number of shares it owns to 1,904. Institutional investors own most of the company’s shares (97.09%). The design, production, and distribution of contact lens wearers are the responsibilities of The Cooper Companies, Inc., together with its subsidiaries and affiliates. The corporation is split into two distinct business segments, which is CooperSurgical and the other is CooperVision.
The CooperVision company provides spherical lenses, which include lenses that correct nearsightedness and farsightedness, as well as toric and multifocal lenses, which include lenses that correct vision issues such as astigmatism, presbyopia, myopia, ocular dryness, and eye fatigue. In addition, the company offers spherical lenses, which include lenses that correct nearsightedness and farsightedness.
In addition, the CooperVision company provides spherical lenses, which may correct both nearsightedness and farsightedness depending on the patient’s needs. These lenses are available for purchase throughout the regions of the Americas, Europe, the Middle East, and Africa, as well as the Asia-Pacific region.
